After $1 Million Drug Flop, UniQure Revives in Gene Therapy (1)

UniQure NV is getting a second chance.

The Dutch biotech company is angling for a comeback in gene therapy after Glybera — its groundbreaking, $1 million treatment for a rare condition — fizzled last year. Now UniQure is shifting the technology to the more-promising market for hemophilia, its once-battered shares have rallied back, and the company may be a takeover target.

Heightened attention from potential partners makes the company feel “a little bit like a beehive,” Chief Scientific Officer Sander van Deventer said in an interview. “There’s not a single week we do not have discussions like that.”

Drugmakers including ...